Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C

Drugs. 2016 Oct;76(16):1567-1578. doi: 10.1007/s40265-016-0648-2.

Abstract

A once-daily, single-tablet, pangenotypic regimen comprising the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir and the HCV NS5A inhibitor velpatasvir (sofosbuvir/velpatasvir; Epclusa®) was recently approved for the treatment of adults with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in the USA, EU and Canada. In the phase III ASTRAL trials, once-daily oral sofosbuvir/velpatasvir for 12 weeks provided very high rates of sustained virological response at 12 weeks post treatment (SVR12) in treatment-naive and -experienced patients with chronic HCV genotype 1-6 infection, including those with compensated cirrhosis or HIV-1 co-infection. High SVR12 rates were also observed with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with chronic HCV genotype 1-6 infection and decompensated cirrhosis. Sofosbuvir/velpatasvir was generally well tolerated, with low rates of adverse events. Thus, sofosbuvir/velpatasvir represents a valuable treatment option in adults with chronic HCV genotype 1-6 infection, including those with compensated or decompensated cirrhosis, previous treatment experience or HIV-1 co-infection.

Publication types

  • Review

MeSH terms

  • Adult
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Carbamates / administration & dosage*
  • Carbamates / chemistry
  • Carbamates / pharmacology*
  • Drug Administration Schedule
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / metabolism
  • Hepatitis C, Chronic / virology
  • Heterocyclic Compounds, 4 or More Rings / administration & dosage*
  • Heterocyclic Compounds, 4 or More Rings / chemistry
  • Heterocyclic Compounds, 4 or More Rings / pharmacology*
  • Humans
  • Liver Cirrhosis / drug therapy*
  • Ribavirin / administration & dosage*
  • Ribavirin / pharmacology
  • Ribavirin / therapeutic use
  • Sofosbuvir / administration & dosage*
  • Sofosbuvir / pharmacology
  • Sofosbuvir / therapeutic use
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Carbamates
  • Heterocyclic Compounds, 4 or More Rings
  • Ribavirin
  • velpatasvir
  • Sofosbuvir